This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Neuroendocrine tumors

Histone
deacetylase 10
(HDAC10)

Computational and cell culture studies suggest HDAC10 inhibitors could enhance chemotherapy in treating neuroblastoma. In a database of patients with advanced-stage neuroblastoma, high HDAC10 expression correlated with poor overall survival. In neuroblastoma cells, HDAC10-targeting small hairpin RNA increased doxorubicin-mediated cell death compared with control shRNA. Next steps include targeting HDAC10 in animal tumor models.

SciBX 6(29); doi:10.1038/scibx.2013.756
Published online Aug. 1, 2013

Patented; available for licensing

Oehme, I. et al. Proc. Natl. Acad. Sci. USA; published online June 25, 2013;
doi:10.1073/pnas.1300113110
Contact: Ina Oehme, German Cancer Research Center, Heidelberg, Germany
e-mail:
i.oehme@dkfz.de